Does the basic therapy affect the development of secondary amyloidosis in rheumatoid arthritis?

Anti-rheumatic drug treatments were studied in 260 patients from Finland and Russia suffering from rheumatoid arthritis (RA) with or without biopsy-proven secondary amyloidosis (RSA). Chloroquine was used for longer period in RSA group in Russia (p = 0.003) and in Finland (p = 0.06). In Finland chlo...

Full description

Saved in:
Bibliographic Details
Published inTerapevtic̆eskii arhiv Vol. 67; no. 5; p. 47
Main Authors Prokaeva, T B, Alekberova, Z S, Radenska-Lopovok, S G, Tiitinen, S, Kaarela, K, Kautiainen, H
Format Journal Article
LanguageRussian
Published Russia (Federation) 1995
Subjects
Adult
Amyloidosis - diagnosis
Amyloidosis - etiology
Amyloidosis - prevention & control
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - drug therapy
Chi-Square Distribution
Female
Finland
Humans
Male
Middle Aged
Russia
Statistics, Nonparametric
Time Factors
Finland
Russia
Online AccessGet more information

Cover

More Information
Summary:Anti-rheumatic drug treatments were studied in 260 patients from Finland and Russia suffering from rheumatoid arthritis (RA) with or without biopsy-proven secondary amyloidosis (RSA). Chloroquine was used for longer period in RSA group in Russia (p = 0.003) and in Finland (p = 0.06). In Finland chloroquine was used more often in the RSA group (p = 0.02), and sulphasalazine (p = 0.02), D-penicillamine (p = 0.03) and cytotoxics (p = 0.04) in the control group. The role of therapy in the prevention of RSA in chronic inflammation is discussed.
ISSN:0040-3660